ME Valuation Metrics
ME Stock Price Metrics
ME Dividend Metrics
ME Growth Rate Metrics
ME Discounted Cash Flow Metrics
| Fair Value Price | - |
| Margin of Safety | - |
ME Revenue Metrics
ME PE Ratio Metrics
| PE Ratio | - |
| PE Ratio Avg TTM | - |
| PE Ratio Avg 3Y | - |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
ME PS Ratio Metrics
| PS Ratio | 0.10 |
| PS Ratio Avg TTM | 0.33 |
| PS Ratio Avg 3Y | 1.16 |
| Current VS TTM Avg | -69.55% |
| Current VS 3Y Avg | -91.36% |
| Current VS 5Y Avg | -96.36% |
ME PB Ratio Metrics
| PB Ratio | 0.51 |
| PB Ratio Avg TTM | 0.50 |
| PB Ratio Avg 3Y | 0.88 |
| Current VS TTM Avg | +2.66% |
| Current VS 3Y Avg | -41.87% |
| Current VS 5Y Avg | -54.02% |
ME Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | - |
| PFCF Ratio Avg TTM | - |
| PFCF Ratio Avg 3Y | - |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
ME Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.41 |
| Debt/Equity Ratio Avg TTM | 0.27 |
| Debt/Equity Ratio Avg 3Y | 0.25 |
| Current VS TTM Avg | +54.72% |
| Current VS 3Y Avg | +62.38% |
| Current VS 5Y Avg | +20.00% |
ME PEG Ratio Metrics
| PEG Ratio | - |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | - |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
ME FCF Yield
| FCF Yield | (924.20%) |
| FCF Yield Avg TTM | (496.25%) |
| FCF Yield Avg 3Y | (255.12%) |
| Current VS TTM Avg | +86.24% |
| Current VS 3Y Avg | +262.27% |
| Current VS 5Y Avg | +438.92% |
ME Earnings Yield
| Earnings Yield | (1471.24%) |
| Earnings Yield Avg TTM | (866.48%) |
| Earnings Yield Avg 3Y | (444.06%) |
| Current VS TTM Avg | +69.80% |
| Current VS 3Y Avg | +231.32% |
| Current VS 5Y Avg | +393.99% |
ME EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | (0.20) |
| Ev/Ebit Ratio Avg TTM | (0.28) |
| Ev/Ebit Ratio Avg 3Y | (1.89) |
| Current VS TTM Avg | -27.27% |
| Current VS 3Y Avg | -89.39% |
| Current VS 5Y Avg | -97.44% |
ME EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | - |
| Ev/Ebitda Ratio Avg TTM | - |
| Ev/Ebitda Ratio Avg 3Y | - |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
ME EV/Assets Ratio Metrics
| Ev/Assets Ratio | 0.03 |
| Ev/Assets Ratio Avg TTM | 0.41 |
| Ev/Assets Ratio Avg 3Y | 0.25 |
| Current VS TTM Avg | -92.64% |
| Current VS 3Y Avg | -88.04% |
| Current VS 5Y Avg | -93.99% |
ME EV/Sales Ratio Metrics
| Ev/Sales Ratio | 0.02 |
| Ev/Sales Ratio Avg TTM | 0.35 |
| Ev/Sales Ratio Avg 3Y | 0.64 |
| Current VS TTM Avg | -94.36% |
| Current VS 3Y Avg | -96.86% |
| Current VS 5Y Avg | -98.93% |
ME Current Ratio Metrics
| Current Ratio | 0.83 |
| Current Ratio Avg TTM | 1.40 |
| Current Ratio Avg 3Y | 2.39 |
| Current VS TTM Avg | -40.71% |
| Current VS 3Y Avg | -65.31% |
| Current VS 5Y Avg | -64.20% |
ME Quick Ratio Metrics
| Quick Ratio | 0.70 |
| Quick Ratio Avg TTM | 1.29 |
| Quick Ratio Avg 3Y | 2.30 |
| Current VS TTM Avg | -45.53% |
| Current VS 3Y Avg | -69.60% |
| Current VS 5Y Avg | -68.66% |
ME ROIC Metrics
| ROIC | (553.10%) |
| ROIC Avg 3Y | (183.52%) |
| ROIC Avg 5Y | (144.41%) |
| Current VS 3Y Avg | +201.38% |
| Current VS 5Y Avg | +283.00% |
| Current VS 10Y Avg | +328.52% |
ME Return on Assets Metrics
| ROA | (175.67) |
| ROA Avg TTM | (172.19) |
| ROA Avg 3Y | (99.08) |
| Current VS TTM Avg | +2.02% |
| Current VS 3Y Avg | +77.30% |
| Current VS 5Y Avg | +111.28% |
ME Return on Equity Metrics
| ROE | 1050.35 |
| ROE Avg TTM | 348.35 |
| ROE Avg 3Y | 157.32 |
| Current VS TTM Avg | +201.52% |
| Current VS 3Y Avg | +567.63% |
| Current VS 5Y Avg | +1619.44% |
ME Net Profit Margin Metrics
| Net Profit Margin | (147.92%) |
| Net Profit Margin Avg TTM | (225.74%) |
| Net Profit Margin Avg 3Y | (158.88%) |
| Current VS TTM Avg | -34.47% |
| Current VS 3Y Avg | -6.90% |
| Current VS 5Y Avg | +11.94% |
Last Updated: Monday, June 15, 2026
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage